Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, noninferiority SURPRISE phase 3b trial - Beyer-Westendorf, J; Schellong, SM; Gerlach, H; Rabe, E; Weitz, JI; Jersemann, K; Sahin, K; Bauersachs, R; SURPRISE investigators (Lancet Haematol, 2017)
Mar;